{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-268816","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.945969+00:00","generated_at":"2026-06-09T00:31:35.894910+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Intellia reports new Phase 1 data for NTLA-2001: median TTR reduction 91%, 55mg dose selected for Phase 3","bullets":["Median serum TTR reduction of 91% and median residual TTR of 17 µg/mL at day 28 across 62 patients (doses ≥0.3 mg/kg).","29 patients with ≥12 months follow-up show sustained TTR reduction; no loss of activity over time.","NTLA-2001 generally well tolerated; infusion-related reactions in 38% (mostly Grade 1-2); no dose-limiting toxicities.","55 mg fixed dose selected for global pivotal Phase 3 trial, expected to begin by year-end 2023; FDA IND clearance received."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-268816","json":"https://secwatch.observer/filing/0001193125-23-268816.json","markdown":"https://secwatch.observer/filing/0001193125-23-268816.md","text":"https://secwatch.observer/filing/0001193125-23-268816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312523268816/0001193125-23-268816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312523268816/d536006d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:31:35.894910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}